Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the p53–MDM2 interaction to treat cancer

28 Sept 2004

Abstract excerpt

The tumour suppressor p53 is a transcription factor with powerful antitumour activity that is controlled by its negative regulator MDM2 (mouse double minute 2, also termed HDM2 in humans) through a feedback mechanism. MDM2, which is overproduced in many tumours, binds p53 and inhibits its function by modulating its transcriptional activity and stability. Activation of p53 in tumour cells by inhibiting its...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Epigenetics and DNA Methylation
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15452548
DOI: 10.1038/sj.bjc.6602164

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the p53–MDM2 interaction to treat cancerPMID 15452548Read ↗

Targeting the MDM2-p53 Interaction for Cancer TherapySemantic proximity Read ↗

Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?Semantic proximity Read ↗

Small Molecule Inhibitors of the p53-MDM2Semantic proximity Read ↗

Clinical Overview of MDM2/X-Targeted TherapiesSemantic proximity Read ↗

Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present)Semantic proximity Read ↗

MDM2: current research status and prospects of tumor treatmentSemantic proximity Read ↗

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trialsSemantic proximity Read ↗

Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?Semantic proximity Read ↗

Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer TherapySemantic proximity Read ↗

Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of ActionSemantic proximity Read ↗

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2Semantic proximity Read ↗

Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell DeathSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.